AVTX
Avalo Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Revenue Decline
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AVTX
Avalo Therapeutics, Inc.
A biopharmaceutical company that developing treatments for rare and orphan diseases
1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087
--
Avalo Therapeutics, Inc., was incorporated in Delaware on January 31, 2011. The Company is a biopharmaceutical company that discovers, develops and commercializes targeted therapies for patients with needs in immunology, immuno-oncology and rare genetic diseases. The company has built a diverse portfolio of innovative therapies that deliver meaningful medical impact to patients in dire need. The company's clinical drug candidates often have proven mechanical principles, biomarkers or established proof-of-concept to expedite and increase the likelihood of success.
Company Financials
EPS
AVTX has released its 2025 Q3 earnings. EPS was reported at -2.19, versus the expected -1.64, missing expectations. The chart below visualizes how AVTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
